GAM MitoCan

About

Targeted IV therapy using mitochondrial biomarkers for lung cancer

GAM MitoCan repurposes the investigational drug gamitrinib TPP hexafluorophosphate as a targeted IV therapy for non-small-cell lung cancer (NSCLC). Patients are prescreened for mitochondrial dysfunction through minimally invasive biopsies and blood tests to identify likely responders. As a mitocan therapy, GAM MitoCan selectively disrupts tumour cell mitochondria while sparing healthy tissue. Early use is expected to help patients who do not benefit from immunotherapy, offering a precision option to reduce tumour burden, minimise toxicity, and improve outcomes

Trends

# Health Therapies

University

University of California, Los Angeles

Team

Jocelyn Diane Rodriguez
University of California, Los Angeles
Jocelyn Rodriguez is a PhD candidate studying lung cancer with Dr. David Shackelford in the department of Medicine-Pulmonary & Critical Care at UCLA. She received her bachelor of science degree in Biochemistry from UC Riverside where she studied newly synthesized copper compounds as potential treatments for glioblastoma. Jocelyn received her master's degree from California State Los Angeles under the mentorship of Dr. Nathan Lanning studying mitochondrial metabolic pathways. Jocelyn is passionate about translational research, science communication and advocacy and has served in different leadership roles including: UCLA SACNAS President, UC Student Regent Advocate and current UCLA Hispanic Serving fellow.more
Mary Sedlak
University of California, Los Angeles
Aaliyah Balagtas
University of California, Los Angeles
Samuel Kharpatin
University of California, Los Angeles
Dr. David Shackelford
University of California, Los Angeles